Based on our findings of higher phosphorylation of STAT6, and higher expression of IL-4Rα, we selected the JAK inhibitors, ruxolitinib and tofacitinib, and the anti–IL-4Rα antibody, dupilumab, as drugs to test in vitro as they are all used clinically for treatment of allergic disease (Bacharier et al., 2021; Beck et al., 2014; Bissonnette et al., 2016; Kim et al., 2020). This evidence concerns the gene STAT6 and allergic disease.